Melior Discovery Publications

The paper details an innovative approach that we have developed as a model to evaluate acne therapeutic candidates

This book chapter amongst a collection of works dedicated to drug repositioning presents the concept of “pharmacological pleiotropy”, that its existence is more common than most investigators appreciate, and that it is the “stuff” that provides drug repositioning opportunity.

This paper starts with a historical perspective of drug discovery dating back to the 19th century, and provides a rationale as to why phenotypic screening has historically been as productive as it has and why there likely remains untapped therapeutic potential among compounds less than 300 MWT that are generally overlooked as drug candidates because of their low MWT.

This paper chronicles the trials and tribulations, the successes and failures along the journey of developing a repurposed drug discovered through phenotypic screening. It a hopeful roadmap for others.

This book chapter lays out the rationale for why phenotypic screening is a cost-effective drug discovery tool and illustrates it with clinically validated examples.

This work represents a collaboration between the Greenway lab at the Pennington Biomedical Research Center and provides a mechanistic understanding of observations for weight loss first made by Melior in a phenotypic screen with MLR-1023 and subsequently in an MLR-1023 clinical study.

This paper, the PhD thesis work of Melior’s Lindsey Mayes-Hopfinger, uncovers new understanding in NLRP3 inflammasome activation.

This paper is a narrative that describes the history of Melior’s candidate, MLR-1023, as well as the founding of Melior

If you would like a pdf copy of this paper please send a request to [email protected]